How Chemotherapy Works against Cancer
SEF Chemo: New treatment with no side-effects?
Berkeley Institute International are treating patients with SEF Chemo – a new treatment that is reportedly side-effects free. Here is some info from its website:
For decades, doctors and researchers have been trying to figure a way—without success—to deliver chemo agents directly to cancerous cells without harming healthy tissue. Dr. Matsumura, and his team of dedicated scientists at the ALIN Foundation, tried a different approach: protect the body by using antidotes to neutralize the damage to normal cells and negate the toxic side effects commonly associated with chemotherapy. Dr. Matsumura developed a novel method in their use that produced a powerful new therapy without the dosage-limiting side effects of cancer drugs. While normal cells are protected, cancer drugs can be employed in higher doses to eradicate the dividing cancer cells not protected by the antidote.
Where conventional chemotherapy may destroy only 60% of cancer cells in the body, SEF Chemo®, using a side effect-reducing medicament, may destroy 95% of cancer cells. For this reason, we find tumors shrinking over weeks with SEF Chemo® compared to months with conventional chemotherapy…
SEF Chemo® research is ongoing. We’re continuing to evaluate the new therapy on diverse types of cancer. So far, SEF Chemo® has had positive progress with various types of cancers, but has achieved particular success with bladder, breast, cervical, colon, liver, lung, ovarian, pancreatic, and prostate cancers. Although clinical experience with this therapy is still considered developmental, the high response rates and results showing the therapy’s ability to eradicate numerous cancer types, has motivated the founding of medical centers practicing SEF Chemo® world-wide.
See SEF Chemo page
Low-dose chemotherapy achieved the same desired potency as conventional-dose chemotherapy.
Low dose chemotherapy can be better than or as efficient as maximum tolerated dose.
How effective is chemotherapy?
Chemotherapy and other cancer drugs don’t prolong life for most patients.
As Dr. Ralph Moss (see Dr Mercola article below) points out, chemotherapy is used effectively to treat Acute Iymphocytic leukemia, Hodgkin’s disease, and nonseminomatous testicular cancer. Also, a few very rare forms of cancer, including choriocarcinoma, Wilm’s tumor, and retinoblastoma. – but these only account for between 2% and 4% of all cancers.
Here is the list of those cancers and the percentage of chemotherapeutic effectiveness:
Source: Hope, Medicine & Healing (Available in bookshops)
By Francisco Contreras MD and Daniel E. Kennedy MC
Burketts Lymphoma (stage 1) 90%
Testicular Carcinoma (stages 2-4) 95%
Childhood carcinomas (with rad/surg) 70% – 90%
Nodular Mixed Lymphoma 75%
Childhood Lymphomas 75%
Diffuse Histcocytic Lymphoma 70%
Acute Lymphocytic Leukemia 60%
Hodgkins Lymphoma (stage 1) 95%
Hodgkins disease (stages 3-4) 60%
Update: The Childhood Cancer Study has demonstrated that among adults treated for cancer during childhood, late effects contribute to a high burden of morbidity, including the following:
- 60% to more than 90% develop one or more chronic health conditions.
- 20% to 80% experience severe or life-threatening complications during adulthood.
Proof that cancer patients’ increases in survival is not ‘because of better drugs’
The Failure of Cancer Treatments
Source: People Against Cancer
The inescapable conclusion is that in the existing paradigm, there is no incentive to cure cancer – only to treat it.
In response to claims by the National Cancer Institute (NCI) of the excellent effectiveness of chemotherapy treatments, Dr. Dean Burk, serving as head of the Cytochemistry Division of the NCI, addressed a letter to his boss Dr. Rauscher, which stated, “I submit that a program of FDA-approved [chemotherapy] compounds that yield only five-to-ten percent ‘effectiveness’ can scarcely be described as ‘excellent,’ the more so since it represents the total production of a 30-year effort on the part of all of us in the cancer-therapy field. Even that five-to-ten percent effectiveness,” he adds, “is suspect, possibly being more than offset (in the majority of patients who do not benefit from chemotherapy) by shorter survival and lower quality of remaining life occasioned by the (widely acknowledged) great toxicity of nearly all approved chemotherapies, most of which, are capable of causing cancer in their own right.”
Chemotherapy only makes a minor contribution to cancer survival
Dangerous side-effects of Chemotherapy
Chemotherapy can cause very serious adverse effects – including death.
Breast Cancer drugs Paclitaxel and Herceptin can cause fatal lung disease.
On 16 July, 2019, The Worthing Herald reported on the case Cecilia Francis, known as Celia, died at Worthing Hospital from lung disease induced by the chemotherapy drugs paclitaxel and herceptin, which she was given as ‘add-on’ treatment for breast cancer, on October 28 last year.
An inquest into her death, held at Crawley Coroner’s Court on Friday, July 12, heard that the 61-year-old of Furzeholme, Worthing, had not been informed that pnemonitis, an inflammation of the lungs, was a potentially life-threatening side effect of these drugs in the literature from cancer charities that she was given at hospital.
One dose of 5-FU chemotherapy can kill you if you have a DPD enzyme deficiency.
5-FU (5-fluorouracil) includes the following brand names:
Dihydropyrimidine Dehydrogenase (DPD) is the liver enzyme largely responsible for deactivating and detoxifying more than 80% of 5-FU from the body. Without the DPD enzyme, fluorouracil-based drugs (5-FU and capecitabine) continue to poison the body indefinitely, resulting in overwhelming toxicity, collateral damage, and for some, agonizing death.
There is a blood test to check for the DPD enzyme deficiency, but most cancer patients are not given this test, or even told about it, before they are given 5-FU.
There is also an antidote to 5-FU poisoning called Vistoguard (uridine triacetate), but it must be given within 4 days, and it is very expensive.
Accidental Chemo spill
Breast cancer patients initially treated with tamoxifen have a twofold increased risk of uterine corpus cancer, with particularly high risks seen for rare tumors of the mixed mullerian type.
Platinum-based chemotherapy for ovarian cancer increased the risk of leukemia three- to fourfold, and risk rose with increasing cumulative doses to reach eightfold.
Source: Second Cancers – Landmark Studies (The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute.)
Press Release issued by the US National Cancer Institute:
Study finds elevated risk of certain rare blood cancers after chemotherapy for most solid tumors
Ulrich Abel, PhD, of the University of Heidelberg, is regarded as one of the world’s leading experts on chemotherapy.
In the 1990s, he conducted a study on the benefits of chemotherapy. He reviewed several thousand publications and sought the views of oncologists in over 350 clinics before publishing his results. Here’s what he found:
“With few exceptions, there is no good scientific basis for the application of chemotherapy in symptom-free patients with advanced epithelial malignancy”.
In his book Chemotherapy of Advanced Epithelial Cancer , he stated: “There is no evidence for the majority of cancers that treatment with these drugs exerts any positive influence on survival or quality of life in patients with advanced disease”
Speaking in Stuttgart in 1990, he stated:
“The success of most chemotherapies is appalling. There is no scientific evidence for its ability to extend in any appreciable way the lives of patients suffering from the most common organic cancer. Chemotherapy for malignancies too advanced for surgery, which accounts for 80 percent of all cancers, is a scientific wasteland.”
Risk of stroke
Chemotherapy worsens outcomes in Stage II colon cancer patients.
Chemo can cause cancer to return
New Study Delivers Another Black Eye for Chemotherapy
What if chemotherapy actually helped to spread cancer? Many within the medical and research communities are becoming emboldened to speak out against outdated and failed healing modalities still in use today.
UK Headlines were made in 2015 when a study in the British Journal of Cancer was published claiming 1 in 2 women and 1 in 3 men will develop cancer at some point in their lives. Two years later on June 20, 2017, a report titled Canadian Cancer Statistics 2017 released by the Canadian Cancer Society stated for males, the lifetime cancer risk is 49% and for females it is 45%.
Another study showing the dangers and ineffectiveness of chemotherapy has just been published and it has gone viral. The study titled Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism was published in the journal Science Translational Medicine describing how chemotherapy could allow cancer to spread, and trigger more aggressive tumors. By studying the process of intravasation, or entry of cells into the vasculature, the study’s authors discovered that chemotherapy, in addition to targeting tumor cells, can also increase intravasation. The authors found that chemotherapy increased groups of cells known as tumor microenvironment of metastasis (TMEM) which collectively usher tumor cells into the body’s vasculature. The study discovered that several types of chemotherapy can increase the amounts of TMEM complexes and circulating tumor cells in the bloodstream. Why is this important? The chances of survival dramatically decrease once cancer begins to metastasize through the bloodstream and effect other organs and systems.
Is the recent study the only one painting chemotherapy as a dangerous treatment option? In 2016 a groundbreaking study was commissioned by Public Health England and published in the journal Lancet Oncology. The study represented the first time that national data has been gathered together and analyzed for 30-day mortality after chemotherapy. It found that a larger proportion of patients are actually dying after chemotherapy than in the clinical trials carried out by the drug companies. The death rate in the clinical trials of drug treatments for lung cancer was 0.8%, but in the present study the reality shows it is actually 3%.
By now, many are beginning to understand that one of the problems with chemotherapy is that it doesn’t address the underlying cause(s) of cancer. Chemotherapy originated from an idea and consciousness that was far from idealistic. The whole generation of chemotherapeutic drugs that are being used today, and there are over one hundred of them, developed from poisonous nerve gas created for warfare. As reported in 2012 by Green Med Info, cancer is the second leading cause of death in the developed world, and yet much of the medical and research communities are still in the dark ages when it comes to treating and understanding it. However, in the age of information, great strides are being made by doctors and researchers who are going against the grain of the failed convention ‘wisdom’ in cancer treatment. In addition, individuals are beginning to take responsibility by educating themselves. GreenMedInfo has been at the forefront with the world’s most widely referenced, evidence-based natural medical resource database containing over 30,000 abstracts and articles.
© [Article Date] GreenMedInfo LLC. This work is reproduced and distributed with the permission of GreenMedInfo LLC. Want to learn more from GreenMedInfo? Sign up for the newsletter here http://www.greenmedinfo.com/greenmed/newsletter.
A look at just a few of the chemo (and other) drugs commonly given to cancer patients.
The side-effects listed below are only a sample of the full range of side-effects observed. Please see individual manufacturers site for further details.
Generic Name: Trastuzumab
Brand Names: Herceptin
Condition or Diseases treated: Breast cancer
Information source: herceptin.com
Boxed WARNINGS and Additional Important Safety Information
- Herceptin administration can result in sub-clinical and clinical cardiac failure. The incidence and severity was highest in patients receiving Herceptin with anthracycline-containing chemotherapy regimens
Infusion Reactions; Pulmonary Toxicity
- Herceptin administration can result in serious and fatal infusion reactions and pulmonary toxicity. Symptoms usually occur during or within 24 hours of Herceptin administration.
- Exposure to Herceptin during pregnancy can result in oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death.
- Herceptin administration can result in sub-clinical and clinical cardiac failure. The incidence and severity was highest in patients receiving Herceptin with anthracycline-containing chemotherapy regimens. In a pivotal adjuvant breast cancer trial, one patient who developed CHF died of cardiomyopathy
- Herceptin can cause left ventricular cardiac dysfunction, arrhythmias, hypertension, disabling cardiac failure, cardiomyopathy, and cardiac death
- Herceptin can also cause asymptomatic decline in LVEF
- Herceptin administration can result in serious and fatal infusion reactions
- Infusion reactions consist of a symptom complex characterized by fever and chills, and on occasion include nausea, vomiting, pain (in some cases at tumor sites), headache, dizziness, dyspnea, hypotension, rash, and asthenia
Condition or Diseases treated: Breast cancer
Information source Medicines.ie
Pregnancy. There have been a small number of reports of spontaneous abortions, birth defects and foetal deaths after women have taken Nolvadex, although no causal relationship has been established.
An increased incidence of endometrial cancer and uterine sarcoma (mostly malignant mixed Mullerian tumours) has been reported in association with Nolvadex treatment. The underlying mechanism is unknown, but may be related to the oestrogen-like effect of Nolvadex. Any patients receiving or having previously received Nolvadex, who report abnormal gynaecological symptoms, especially vaginal bleeding, should be promptly investigated.
A number of second primary tumours, occurring at sites other than the endometrium and the opposite breast, have been reported in clinical trials, following the treatment of breast cancer patients with tamoxifen. No causal link has been established and the clinical significance of these observations remains unclear.
According to Second Cancers – Landmark Studies: Breast cancer patients initially treated with tamoxifen have a twofold increased risk of uterine corpus cancer, with particularly high risks seen for rare tumors of the mixed mullerian type.
Manufacturer: Roche Group
Condition or Diseases treated: Metastatic Colorectal Cancer
Information supplied by: Genentech USA
Possible serious side effects
Most serious side effects (not common, but sometimes fatal):
A hole that develops in your stomach or intestine. Symptoms include pain in your abdomen, nausea, vomiting, constipation, or fever
Wounds that don’t heal
A cut made during surgery can be slow to heal or may not fully heal.
This includes vomiting or coughing up blood; bleeding in the stomach, brain, or spinal cord; nosebleeds; and vaginal bleeding.
What are the other possible serious side effects?
% = Percentage of patients who had this side effect in clinical studies across different cancers
Severe high blood pressure 18%
Blood pressure that severely spikes or shows signs of affecting the brain.
Kidney problems 7%
These may be caused by too much protein in the urine and can sometimes be fatal
Infusion reactions 3%
Infusion reactions include high blood pressure or severe high blood pressure that
may lead to stroke
decreased oxygen in red blood cells
a serious allergic reaction
Severe stroke or heart problems 2.6%
These may include blood clots, mini-stroke, heart attack, and chest pain.
These can sometimes be fatal
Abnormal passage in the body 2%
This type of passage—known as a fistula—is an irregular connection from one part of the body to another and can sometimes be fatal
Nervous system and vision problems 0.5%
Signs include headache, seizure, high blood pressure, sluggishness, confusion, and blindness
What are the side effects seen most often?
In clinical studies across different types of cancer, some patients experienced the following side effects:
- High blood pressure
- Too much protein in the urine
- Rectal bleeding
- Back pain
- Taste change
- Dry skin
- Inflammation of the skin
- Inflammation of the nose
- Watery eyes
Condition or Diseases treated: Breast cancer
Information source: Novartis Pharmaceuticals Corporation
WARNINGS AND PRECAUTIONS
- Non-infectious pneumonitis: Monitor for clinical symptoms or radiological changes; fatal cases have occurred.
- Infections: Increased risk of infections, some fatal.
- Renal failure: Cases of renal failure (including acute renal failure), some with a fatal outcome, have been observed.
- Angioedema: Patients taking concomitant ACE inhibitor therapy may be at increased risk for angioedema.
- Oral ulceration: Mouth ulcers, stomatitis, and oral mucositis are common.
- Impaired wound healing: Increased risk of wound-related complications.
- Laboratory test alterations:
Elevations of serum creatinine, urinary protein, blood glucose, and lipids may occur. Decreases in hemoglobin, neutrophils, and platelets may also occur.
- Embryo-Fetal Toxicity: Can cause fetal harm.
Manufacturer: Eli Lilly
Condition or Diseases treated: Non-small cell lung cancer
Information Source: Eli Lilly
ALIMTA can suppress bone marrow function, which may cause low blood cell counts.
Call your doctor right away if you have a fever, chills, diarrhea, or mouth sores. These symptoms could mean you have an infection, which may be severe and could lead to death.
The most common side effects of ALIMTA when given alone or in combination with cisplatin are:
- Stomach upset, including nausea, vomiting, diarrhea, or constipation.
- Low blood cell counts:
- Low red blood cells. Low red blood cells may make you feel tired, get tired easily, appear pale, and become short of breath.
- Low white blood cells. Low white blood cells may give you a greater chance for infection.
- Low platelets. Low platelets give you a greater chance for bleeding. Your doctor will do blood tests to check your blood counts before and during treatment with ALIMTA.
- Tiredness. You may feel tired or weak for a few days after your ALIMTA treatments.
- Redness or sores in your mouth, throat, on your lips, or in the tube that connects your throat and stomach (esophagus). You may get redness or sores in your mouth, throat, on your lips, or in your esophagus (stomatitis, pharyngitis, esophagitis) or you may feel pain or have difficulty when drinking or swallowing food. These symptoms may happen a few days after ALIMTA treatment.
- Loss of appetite. You may lose your appetite and lose weight during your treatment.
- Rash. You may get a rash or itching during treatment. These reactions usually appear between treatments with ALIMTA and usually go away before the next treatment. Skin reactions or rashes that include blistering or peeling may be severe and could lead to death.
- These are not all the side effects of ALIMTA.
Condition or Diseases treated: Prostate cancer
Information supplied by: Drugs.com
- Cardiovascular Diseases:
Increased risk of myocardial infarction, sudden cardiac death and stroke has been reported in association with use of GnRH analogs in men.
- Fast or irregular heartbeat
- Bone, muscle, or joint pain
- changes in skin color of the face
- fast or irregular breathing
- numbness or tingling of the hands or feet
- puffiness or swelling of the eyelids or around the eyes
- skin rash, hives, or itching
- sudden, severe decrease in blood pressure and collapse
- tightness in the chest
- troubled breathing
- Pain in the chest
- pain in the groin or legs (especially in the calves of the legs)
Minor Side Effects
- Sudden sweating and feelings of warmth (also called hot flashes)
- Blurred vision
- burning, itching, redness, or swelling at the place of injection
- decreased interest in sexual intercourse
- nausea or vomiting
- swelling and increased tenderness of the breasts
- swelling of the feet or lower legs
- trouble sleeping
- weight gain
- Bone pain
- decreased size of the testicles
- inability to have or keep an erection.